These patents are key for developing the
AMPAKINE technology for the potential treatment of a variety of clinical indications."
Additionally, the companies have signed a memorandum of understanding (MOU) for the rights to the
AMPAKINE CX1739 for neurodegenerative diseases in South Korea.
29 March 2010 - US-based developer of small molecule compounds Cortex Pharmaceuticals Inc (OTC: CORX) announced on Friday that it has entered into an agreement with Biovail Laboratories International SRL in which Biovail acquired certain
AMPAKINE compounds and the rights to the patent filing for respiratory depression and vaso-occlusive crises associated with sickle cell disease.
(Irvine, CA; 949-727-3157) announced that it has received three patents and three notices of allowances for patents in its
AMPAKINE program.
M2 EQUITYBITES-August 25, 2011-Cortex Pharmaceuticals Inc awarded US patent for
AMPAKINE molecules for respiratory depression(C)2011 M2 COMMUNICATIONS http://www.m2.com
"Cortex and its collaborators at UC Irvine are in the process of initiating a long term experiment in which rats will receive an
AMPAKINE in their drinking water for four to eight months.
M2 EQUITYBITES-August 25, 2011-Cortex awarded patent for the use of
AMPAKINE molecules to treat respiratory depression(C)2011 M2 COMMUNICATIONS http://www.m2.com
For example, treatment of healthy human subjects with an
ampakine, which enhances LTP, improved performance in a dose-dependent manner.
There also is evidence that
ampakine, an investigational drug that modulates glutaminergic alpha-amino-3-hydroxy-5methylisoxazole-4-propionic acid (AMPA) receptor activity, improves "many domains of cognitive function," Dr.
The team, led by Lynch, Julie Lauterborn, and Linda Palmer, wanted to know whether dendritic retraction was already underway in 13-month-old or "middle-aged" rats and, if it was, could they reverse it by giving rats a compound called an
ampakine.
Ampakines had previously been shown to improve age-related cognitive deficits in rats as well as increase production of a key growth factor, brain-derived neurotrophic factor (BDNF) in the brain.
Cortex Pharmaceuticals added that the proceeds may be used to support its clinical development of
ampakines for the treatment of central sleep apnea and opiate induced respiratory depression, commencing with a Phase 2A clinical study of CX1739, the lead
ampakine, as well as to fund corporate general and administrative costs.
Katz, "Brain-derived neurotrophic factor expression and respiratory function improve after
ampakine treatment in a mouse model of Rett syndrome," The Journal of Neuroscience, vol.